BioSpace News Archive

Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2023 after market close on Tuesday, May 2, 2023 at 4:30 PM Eastern Time.

Envista Holdings Corporation (NYSE: NVST) (“Envista”) will report financial results for its first quarter 2023 on Wednesday, May 3, 2023.

IVERIC bio, Inc. reported that on April 3, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.

Johnson & Johnson announced that its subsidiary LTL Management LLC has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan that will equitably and efficiently resolve all claims arising from cosmetic talc litigation against the Company and its affiliates in North America.

Rocket Pharmaceuticals, Inc., a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced expansion of its leadership team to support its growing and industry-leading pipeline of AAV and LV gene therapy assets and evolution towards commercial stage.

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 11,800 shares of the Company’s common stock, effective as of April 3, 2023.

Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”) today announced that the Company entered into the warrant agreement (the “Warrant Agreement”) and finalized the related ancillary documents required under the credit facility with the European Investment Bank (“EIB”) (the “Finance Contract”) for up to €40 million previously announced on December 28, 2022.

Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, announced that management will participate in a virtual fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023 at 12:45 p.m. Eastern Time.

Dr. Hamid Abbasi, a renowned spine surgeon and innovator, has successfully performed the first Inspired Spine Trans-Kambin Oblique Lateral Lumbar Interbody Fusion with Arrow Cage in South America.

Protagonist Therapeutics announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share.